Hydrogen sulphide in liver glucose/lipid metabolism and non-alcoholic fatty liver disease

Inês Mateus | Carina Prip-Buus

Institut Cochin, INSERM, CNRS, Université de Paris, Paris, France

Correspondence
Carina Prip-Buus, Institut Cochin, INSERM U1016, CNRS UMR 8104; Department of Endocrinology, Metabolism and Diabetes, 24 Rue du Faubourg Saint-Jacques, 75014, Paris, France.
Email: carina.prip-buus@inserm.fr

Present address
Inês Mateus, Institut Cochin, INSERM U1016, CNRS UMR8104, Université de ParisParis, France

Funding information
This study was financially supported by the European Union’s Horizon 2020 Research and Innovation programme under the Marie Sklodowska-Curie Grant Agreement No. 722619 project ‘FOIE GRAS’ and by the Société Francophone du Diabète (SFD-Johnson & Johnson Diabetes Care Compagnie 2017)

Abstract

Background: For a long time, hydrogen sulphide (H₂S) was considered only as a toxic gas, inhibiting mitochondrial respiration at the level of cytochrome c oxidase, and an environmental pollutant. Nowadays, H₂S is recognized as the third mammalian gasotransmitter, playing an important role in inflammation, septic shock, ischaemia reperfusion events, cardiovascular disease and more recently in liver physiology and chronic liver diseases such as non-alcoholic fatty liver disease (NAFLD).

Methods: This narrative review is based on literature search using PubMed.

Results: From a bioenergetic perspective, H₂S is a very unique molecule, serving as a mitochondrial poison at high concentrations or as an inorganic mitochondrial substrate at low concentrations. By using transgenic animal models to specifically modulate liver H₂S biosynthesis or exogenous compounds that release H₂S, several studies demonstrated that H₂S is a key player in liver glucose and lipid metabolism. Liver H₂S content and biosynthesis were also altered in NAFLD animal models with the in vivo administration of H₂S-releasing molecules preventing the further escalation into non-alcoholic-steatohepatitis. Liver steady-state levels of H₂S, and hence its cell signalling properties, are controlled by a tight balance between its biosynthesis, mainly through the transsulphuration pathway, and its mitochondrial oxidation via the sulphide oxidizing unit. However, studies investigating mitochondrial H₂S oxidation in liver dysfunction still remain scarce.

Conclusions: Since H₂S emerges as a key regulator of liver metabolism and metabolic flexibility, further understanding the physiological relevance of mitochondrial H₂S oxidation in liver energy homeostasis and its potential implication in chronic liver diseases are of great interest.

KEYWORDS
hydrogen sulphide, liver, metabolism, mitochondria, non-alcoholic fatty liver disease
1 | INTRODUCTION

Hydrogen sulphide (H$_2$S) is the third gasotransmitter discovered in mammals besides carbon monoxide (CO) and nitric oxide (NO).\(^1\) Easily recognizable by its characteristic scent of rotten eggs, H$_2$S is considered an environmental pollutant, and its toxic effects in humans have been thoroughly described.\(^2\) Nowadays, H$_2$S still constitutes the number one occupational hazard at oil and gas field wellheads, pipelines, processing plants and refineries.\(^3\) Much of its toxicity relies on the fact that, similarly to cyanide, NO and CO, H$_2$S inhibits mitochondrial cytochrome c oxidase (Complex IV), hence blocking mitochondrial respiration.\(^4\) Nonetheless, the public concern for its lethal effects was so great that the physiological importance of this gas was completely overlooked until the late 1990s.\(^5\) It was not until 2001 that a physiological role for H$_2$S has been reported in cardio-vasorelaxation.\(^6\) Since then, thousands of studies were conducted to better understand and clarify the role of H$_2$S in a given system. The general assessment is that, as a gasotransmitter, H$_2$S acts as a pleiotropic agent, playing an active role in multiple physiological situations: vasorelaxation,\(^7,8\) angiogenesis,\(^9\) apoptosis,\(^10,11\) ageing\(^12\) and metabolism.\(^13,14\) The biological importance of H$_2$S became more complex with the discovery that H$_2$S can also serve as an inorganic substrate for mammalian mitochondrial respiration through its oxidation by a mitochondrial sulphide quinone oxido-reductase (SQR).\(^15\) The presence of the SQR in many different cell types/organs of the mammalian organism suggests that tissue H$_2$S levels have to be tuned either to avoid toxic accumulation or to control H$_2$S signalling.

Over the past decades, the potential role of H$_2$S in liver pathophysiology has emerged.\(^16\) Liver metabolism is central to energy homeostasis, and liver metabolic inflexibility is known to be associated with several metabolic diseases, such as non-alcoholic fatty liver disease (NAFLD). The liver is uniquely positioned to be exposed to high levels of H$_2$S originating from the gut microbiota and from endogenous biosynthesis essentially via the transsulphuration pathway.\(^17\) In this review, we discuss the roles of H$_2$S in the regulation of liver metabolism and NAFLD development, with a particular focus on hepatic H$_2$S biosynthesis and mitochondrial oxidation and their potential exploitation as targeted therapeutic approaches.

2 | LIVER SOURCES OF H$_2$S

Liver H$_2$S levels were previously reported within the low nanomolar to middle micromolar range (17 nM-144 µM).\(^18-20\) Although some of the H$_2$S found in the body comes from inhalation, the majority of it is produced within the organism through the catabolism of dietary amino acids in tissues and through microbiota fermentation. Whether H$_2$S is of endogenous (hepatic non-enzymatic and enzymatic reactions) or exogenous (gut microbiota) sources, the liver is exceedingly likely to be exposed to high levels of H$_2$S (Figure 1).

2.1 | Endogenous non-enzymatic H$_2$S production

In mammals, non-enzymatic H$_2$S can be produced in the presence of reducing agents such as glutathione (GSH), nicotinamide adenine dinucleotide (NADH) and nicotinamide adenine dinucleotide phosphate (NADPH).\(^21\) H$_2$S can also be released from bound sulphur as well as organic or inorganic polysulphides\(^21,22\) (Figure 1). An additional non-enzymatical way to produce H$_2$S is through thiosulphate.\(^21\) Koj et al.\(^23\) reported that glutathione disulphide (GSSG), H$_2$S and labelled sulphite were produced when rat liver mitochondria were incubated with oxygen, GSH, and $[^{35}S]$thiosulphate. Other sources of non-enzymatic H$_2$S production can include thiocystine and cysteine.\(^21\) Indeed, the occurrence of coordinated catalysis of cysteine with ferric iron and vitamin B6 leads to dose-dependent intravascular release of abundant H$_2$S.\(^24\) Such non-enzymatic H$_2$S generation is likely to occur in the liver, a tissue that usually holds iron storages. Presently, the existence and the physiological relevance of these non-enzymatic H$_2$S productions in the liver still remain to be fully addressed.

2.2 | Endogenous enzymatic H$_2$S biosynthesis

In the liver, sulphur-containing amino acids, such as homocysteine, cysteine and methionine, are metabolized during the transsulphuration pathway, in which H$_2$S is released as a by-product\(^17\) (Figure 1). The reactions constituting this pathway are essentially mediated by three enzymes: cystathionine $\beta$-synthase (CBS), cystathionine $\gamma$-lyase (CSE) and 3-mercaptopypyruvate sulphurtransferase (MPST).

While CBS is mainly expressed in the central nervous system, CSE and MPST are mainly expressed in the peripheral tissues.\(^5,25-27\) In the liver, all three enzymes are highly detectable, although the CBS/CSE system is thought to be responsible for the majority of hepatic H$_2$S production while MPST plays a secondary role. Previous studies have shown that CSE is about 60-fold more expressed than CBS in the liver\(^28\) and that mice with a global invalidation of the CSE gene presented 50% less serum H$_2$S levels.\(^26\) Nevertheless, each enzyme uses a specific combination...
of substrates and contributes differently to the total H$_2$S pool. At physiologically relevant concentrations of substrate, 70% of all H$_2$S is produced from CSE-mediated reactions. However, H$_2$S is majorly synthetized as a by-product during the metabolism of sulphur-containing amino acids, such as homocysteine and cysteine, in the transsulphuration pathway, which involves cysteine β-synthase (CBS), cysteine γ-lyase (CSE), 3-mercaptopyruvate sulphurtransferase (MPST) and cysteine aminotransferase (CAT). H$_2$S is a strong mitochondrial poison when present at high concentrations, and cells have developed a system to maintain non-toxic levels of H$_2$S: the sulphide oxidizing unit (SOU). The mitochondrial oxidation of H$_2$S molecules conducted by the SOU generates electrons and protons that are injected into the mitochondrial electron transport chain, which makes H$_2$S the first inorganic energetic substrate used by mammalian cells and that H$_2$S infusion in the portal circulation had a direct impact on hepatic bioenergetics and oxygen availability. Thus, the gut-liver axis plays a key role not only in liver H$_2$S availability but also in H$_2$S clearance and liver physiology. Moreover, gut microbiota also represents a major regulator of the systemic bioavailability of H$_2$S since germ-free mice have up to 80% less plasma-free H$_2$S level than conventional mice. Two classes of microorganisms produce considerable amounts of H$_2$S: the cysteine fermenters (e.g. *Escherichia coli*, *Salmonella enterica*, *Clostridia* and *Enterobacter*) and the sulphate-reducing bacteria (SRB) (e.g. *Desulfovibrio*, *Desulfobacter*,(458,609),(593,665) and *Desulfothricum*) (Figure 1). As their name suggests, cysteine fermenters produce H$_2$S, pyruvate and ammonia from the fermentation of cysteine by cysteine desulphhydrase, while SRB produce H$_2$S via the reduction of inorganic sulphate or via microbial catabolism of sulphomucins.

H$_2$S concentrations in the gut luminal content are usually found within the millimolar range (0.2–1.5 mM for rodents and up to 3.4 mM for humans). Since H$_2$S is
notably produced from sulphur-containing amino acids, high-protein diets (HPD) can modify gut microbiota composition towards the growth of H₂S-producing bacteria. Indeed, rats fed HPD presented a higher abundance of SRB and higher concentrations of colonic H₂S. Similarly, individuals fed a high-meat diet for 10 days have 15 times more faecal sulphide than individuals fed a vegetarian diet for the same period of time. H₂S production by intestinal bacteria also escalated during cases of inflammatory bowel disease. Given that H₂S can be extremely toxic, colonocytes exposed to high levels of H₂S are able to develop adaptive metabolic response and increase their capacity for mitochondrial H₂S oxidation to limit the adverse effects of H₂S.

3 | H₂S AND MITOCHONDRIA: A DUAL FACED MOLECULE

At a molecular level, H₂S toxic properties are attributed to the inhibition of mitochondrial Complex IV. Complex IV catalyses the transfer of electrons from reduced cytochrome c to molecular oxygen (Figure 2). It has been established in several tissues including the liver that, at high concentrations (typically 10–100 µM), H₂S competitively binds to Complex IV, thereby inhibiting the binding of oxygen. While some studies suggested that this H₂S-induced inhibition led to increased mitochondrial levels of reactive oxygen species (ROS), other studies suggested that Complex IV inhibition by H₂S decreased ROS levels by increasing the activity of superoxide dismutases (SODs).

Nonetheless, H₂S actions on mitochondria are far more complex than those of a simple poison. Due to its highly toxic properties, microorganisms that dwell in sulfidic habitats must have efficient ways to survive in such abiotic conditions. Thorough investigations showed that H₂S was not only tolerated by these microorganisms, but rather exploited in an endosymbiotic way. In 1986, H₂S oxidation coupled to adenosine triphosphate (ATP) production was described in mitochondria isolated from the mussel Solemya reidi. Subsequent studies conducted in the lugworm Arenicola marina showed that mitochondrial H₂S oxidation was linked to the electron transfer chain (ETC) at the level of ubiquinone via a sulphide quinone oxidoreductase (SQR). Later, Hildebrandt and Grieshaber demonstrated that SQR did not act alone in this process, but was rather part of a larger pathway in which also participate ethylmalonic encephalopathy protein 1 (ETHE1), thiosulphate sulphurtransferase (TST) and sulphite oxidase (SUOX) (Figure 2). This set of four enzymes, nowadays recognized as the sulphide oxidizing unit (SOU), conducts the transformation of H₂S into sulphone, thiosulphate and sulphate, respectively. In 2007, Goubern et al. demonstrated that not only bacteria and invertebrates but also mammalian cells used H₂S as an inorganic substrate via its oxidation in mitochondria.

**FIGURE 2** Mitochondrial H₂S oxidation in a mammalian cell. The sulphide oxidizing unit (SOU) allows H₂S to be used as an inorganic energetic substrate for mammalian mitochondria. H₂S is initially oxidized by sulphide quinone oxidoreductase (SQR), generating an SQR-bound persulphide (SQR-SSH) and releasing electrons (e−) that are transferred to ubiquinone (Q) and carried down the electron transport chain. The SQR-SSH is transferred to a small molecule acceptor such as glutathione (GSH), forming a molecule of glutathione persulphide (GSSH) in the process. GSSH is then converted, with O₂ and H₂O as co-substrates, by ethylmalonic encephalopathy protein 1 (ETHE1, a sulphur dioxygenase) to sulphite (SO₃²⁻). The sulphite formed can either be converted, with GSSH as co-substrate, into thiosulphate (S₂O₃²⁻) by thiosulphate sulphurtransferase (TST, also called rhodanese) or be directly used by sulphite oxidase (SUOX) to produce sulphate (SO₄²⁻).
Almost all cells present the capacity to oxidize H₂S. In the central nervous system, only neurons, oligodendrocytes and endothelial cells present SQR protein expression.⁵⁹ In mammals, the main sites of sulphide oxidation are the liver, kidney and colon.⁵⁰,⁵¹ The liver capacity to oxidize H₂S appears to be species-dependent, with human liver mitochondria showing the highest oxidation rates followed by pig, rat and finally mouse.⁵²,⁵³ From a mitochondrial bioenergetic point of view, H₂S is a very peculiar molecule, with a double-face effect on mitochondrial respiration: serving as an inorganic energetic substrate at low concentrations (nanomolar up to 10 µM) since H₂S oxidation exceeds its delivery rate and preserves mitochondrial respiration, or as an inhibitory molecule of mitochondrial Complex IV at higher concentrations (above 10 µM) when H₂S oxidation is lower than its delivery rate.⁵⁴-⁵⁶ Consequently, a marginal decrease in mitochondrial respiration may initiate a vicious cycle of H₂S accumulation leading to a block in respiration. The positive bioenergetic effects of H₂S required a basal activity of the Krebs cycle and is most pronounced at intermediate concentrations of succinate.⁵⁴ However, the concept of H₂S duality has recently been challenged by showing that high concentrations of sodium hydro-sulphide (NaHS) (50–300 µM), an H₂S-releasing molecule, induced persulphidation of the α subunit of ATP synthase (ATP5A1) in HepG2 cells, rendering the ATP synthase enzyme more active.⁵⁷

## 4 | H₂S AS A REGULATOR OF LIVER METABOLISM

The liver is a key player in mammalian physiology with respect to energy homeostasis. It converts food nutrients absorbed by the intestine into substrates that the body can use (glucose, fatty acids [FA], amino acids...) and/or stores them (glycogen, triglycerides [TG]) before supplying them to cells when needed.⁵⁸ In addition, being the gateway to the body, the liver is also the main detoxification organ, able to metabolize and neutralize harmful substances, drugs, environmental toxins and endotoxins.⁵⁹,⁶⁰

Although it is widely accepted that the liver is exceedingly well positioned to be exposed to elevated levels of H₂S, it still remains unknown how the liver copes with fluctuations in H₂S levels. Being a gas, H₂S can rapidly diffuse across membranes and react with different biological matrixes (e.g., proteins, haeme, GSH...), which makes this molecule incredibly hard to quantify. Therefore, up to now, this question has been indirectly addressed by using either transgenic knock-out (KO) CSE or CBS mouse models or exogenous H₂S donors (molecules that release H₂S under in vivo or in vitro conditions) such as sulphide salts (NaHS and sodium sulphide [Na₂S]), natural donors (garlic-based compounds) or slow-release molecules (GYY4137) (Figure 3).

### 4.1 | Studies targeting endogenous H₂S biosynthesis

Multiple studies reported that H₂S is an active modulator of different metabolic processes, such as glucose utilization,¹³ gluconeogenesis,¹³,¹⁴,⁶¹ lipolysis,⁶²,⁶³ adipogenesis,⁵⁵ insulin signalling⁶⁴ and insulin resistance (IR),⁶⁵,⁶⁶ with CSE and CBS being essential for liver lipid and glucose metabolism (Figure 3).

#### 4.1.1 | Impact on hepatic glucose metabolism

Although hepatic H₂S can originate from CBS-mediated reactions, most studies assessing the role of H₂S in liver glucose metabolism focused on the CSE/H₂S system. Liver glycogen content and glucose consumption were higher in CSE KO mice compared with wild-type mice.¹³ Adenovirus-mediated CSE overexpression increased endogenous H₂S production and decreased glycogen content in HepG2 cells whereas incubation of HepG2 cells with NaHS impaired glucose uptake and glycogen storage via decreasing glucokinase (GK) activity¹³ (Figure 3). Overnight-fasted CSE KO mice submitted to a pyruvate tolerance test had a lower rate of gluconeogenesis than wild-type mice, which was normalized by in vivo administration of NaHS through the upregulation of key gluconeogenic transcription factors such as peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) and CCAAT/enhancer-binding protein beta.⁶¹ NaHS also upregulated the expression and the activity by persulphidation of glucose-6-phosphatase (G6Pase) and fructose-1,6-bisphosphatase (F1,6Pase). NaHS was further shown to stimulate pyruvate carboxylase (PC) activity and gluconeogenesis in HepG2 cells and mouse hepatocytes¹⁴ (Figure 3). CSE overexpression enhanced but CSE KO reduced PC activity and gluconeogenesis, and blockade of PC activity abolished H₂S-induced gluconeogenesis.¹⁴ In addition, insulin at the physiological range inhibited CSE expression, and H₂S decreased insulin-stimulated phosphorylation of the protein kinase B (Akt) in HepG2 cells. However, hepatic CSE expression was increased in an in vitro model of liver IR¹³ and in streptozotocin-induced diabetic rats.⁶⁷
4.1.2 | Impact on hepatic lipid metabolism

Humans carrying a CBS variant and CBS KO mice exhibited the same traits of hyperhomocisteinemia, oxidative stress, liver steatosis and fibrosis.68,69 CBS KO mice displayed altered mRNA levels of proteins required for cholesterol and FA biosynthesis and uptake, namely up-regulation of liver X receptor (LXR), ATP binding cassette subfamily G member 1, 5 and 8 and ATP binding cassette subfamily A member 1, and down-regulation of peroxisome proliferator receptor alpha (PPARα).70,71 (Figure 3). These animals have also increased plasma levels of TG and non-esterified FA as well as lower hepatic activity of thiolase, a key enzyme for mitochondrial FA ß-oxidation.70 Recent evidence supported these findings by showing that CBS KO rabbits had higher plasma levels of TG and total cholesterol and low-density lipoprotein as well as hepatic microvesicular steatosis.72 CBS KO mice also showed significant alteration of a broad range of hepatic phospholipids and phosphatidylcholines.73 Similarly, inhibition of hepatic CSE expression in a foetal hepatocyte line (LO2) upregulates the sterol regulatory element-binding protein 1 (SREBP-1c) pathway, c-Jun N-terminal kinase (JNK) phosphorylation and hepatic oxidative stress.74

4.2 | Studies targeting mitochondrial H₂S oxidation

Although most studies published thus far largely concern the regulation of H₂S levels through the modulation of its biosynthesis, hepatic mitochondrial H₂S oxidation may also regulate the levels of this gasotransmitter in the liver and hence its actions (Figure 2). Unfortunately, not many studies have been conducted to enlighten the physiological relevance of this pathway in liver energy homeostasis. SQR KO models of Caenorhabditis elegans exposed to H₂S exhibited increased phosphorylation of eukaryotic translation initiation factor 2-alpha with subsequent inhibition of protein synthesis.75 The organism also presented activation of endoplasmic reticulum and mitochondrial stress responses.75 In humans, it has been recently reported the existence of two homozygous pathogenic variants of SQR, responsible for lack of protein and enzyme activity. The first variant (c.637G > A) was associated with decreased Complex IV activity in liver and muscle, lactic acidosis, hypotonicity, brain lesions and multiorgan failure.76 The second variant (c.446delT) was associated with lactic acidosis, ketosis, dicarboxylic aciduria, Complex IV inhibition, encephalopathy and basal ganglia lesions. In all patients, the symptoms were triggered by infections or fasting, episodes associated with protein catabolism.76 SQR has also been shown to be required for H₂S-mediated protection during nutrient/oxygen deprivation in Hepa1-6 cells.77 In this study, addition of exogenous NaHS reduced lactate dehydrogenase (LDH) release (a marker of cell damage) in control Hepa1-6 cells during the ischaemic phase and upon reperfusion whereas LDH release was upregulated in cells partially depleted of SQR.77 This study revealed that the resistance to ischaemia/reperfusion was linked to SQR capacity in donating electrons to the ETC via ubiquinone.77

A complex interplay and feedback mechanism(s) may exist between the pathways of H₂S production and oxidation and their regulation. Dietary restriction (DR) was shown to enhance hepatic H₂S production by the upregulation of liver CSE via the activation of mechanistic target of rapamycin (mTOR).77 This increased CSE expression presumes higher cysteine degradation into H₂S while cysteine concentrations are low in the context of DR, which appears to be counterintuitive.77 However, the in vivo sources and substrates for CSE-derived H₂S production in cases of DR are not known, and free cysteine residues released upon autophagy could be a major fuel source for H₂S production. Additionally, Shirozu et al.78 showed that hepatic H₂S levels in CSE KO mice were not significantly different from those found in control mice and that liver SQR mRNA and protein levels were increased, which is unexpected in a model of H₂S insufficiency. Therefore, further investigations are essential to better explore the
importance of SQR in liver metabolism and its interplay with the CSE/H₂S pathway.

5 | H₂S IN NON-ALCOHOLIC FATTY LIVER AND NON-ALCOHOLIC STEATOHEPATITIS

Non-alcoholic fatty liver disease (NAFLD) has been increasingly recognized as a major health burden in developed countries. Recent studies emphasize the role of IR, oxidative stress, lipid peroxidation, pro-inflammatory cytokines, adipokines and mitochondrial dysfunction in the onset and progression of non-alcoholic fatty liver (NAFL) towards non-alcoholic steatohepatitis (NASH). Over the past few years, several studies have reported alterations of H₂S metabolism in both human and animal models of NAFLD (Table 1).

5.1 | Changes in H₂S biosynthesis

Some studies reported significant lower hepatic H₂S levels or CBS and CSE activities in mice and rats fed high-fat diet (HFD) when compared to control animals. These results have been corroborated by human studies, given that overweight individuals present lower plasma H₂S levels when compared to lean controls. Hepatic H₂S biosynthesis was also impaired in a diet-induced rat model of NASH. Nonetheless, other studies reported that H₂S biosynthesis was upregulated in HFD-fed mice and obese diabetic rats. The discrepancies between these studies may either arise from differences in the composition of the diets and/or the duration of feeding or reflect spectrum-specific responses of these enzymes during the evolution of NAFLD.

Recently, CSE KO mice were shown to be more prone to develop obesity and IR when fed HFD as CSE inactivation aggravated obesity-related IR by inhibiting hepatic Akt activity and repressing forkhead box protein O1 (FoxO1) phosphorylation and degradation. This resulted in the accumulation of nuclear FoxO1 and upregulation of phosphoenolpyruvate carboxykinase (PEPCK) and G6Pase, leading to increased gluconeogenesis. Additional evidence demonstrated that CSE KO mice fed HFD had increased plasma and liver cholesterol levels due to decreased mRNA levels of LXR and the LXR-target gene cytochrome P450 family 7 subfamily A member 1 (CYP7A1), which halted cholesterol catabolism favouring its accumulation. According to this study, deficiencies in the CSE/H₂S pathway might result in high susceptibility to HFD-induced fatty liver. In fact, HepG2 cells incubated with a mixture of free FA or high glucose concentration exhibited lower levels of CSE expression and H₂S production, as well as enhanced intracellular levels of acetyl-CoA and lipids. Experiments using CSE KO mice fed high-fat/choline-deficient diet corroborated these results by showing hepatic accumulation of acetyl-CoA and lipids.

| TABLE 1 | Studies reporting changes in H₂S biosynthesis and H₂S levels in cases of non-alcoholic fatty liver disease (NAFLD) |

| Diet/Genetic Model | Observations | References |
|--------------------|--------------|------------|
| Animal models      |              |            |
| HFD NAFL           | ↓ liver CSE and MPST protein expression | 81 |
| HFD NAFL           | ↓ liver H₂S content | 74 |
| HFD NAFL           | ↑ liver MPST and ↓ liver CSE protein expression | 74 |
| HFD NAFL           | ↓ hepatic levels of H₂S | 74 |
| Zucker diabetic fatty rats NAFL | ↑ liver CSE and CBS mRNA and protein | 85 |
| MCD NASH           | ↓ liver CSE and MPST mRNA expression | 84 |
| HFD NAFL           | ↓ liver and plasma H₂S levels | 82 |
| Humans             |              |            |
| Overweight         | ↓ plasma H₂S levels | 83 |
| Obese with T2DM    | ↓ plasma H₂S levels | 83 |
| Overweight         | ↑ liver MPST and ↓ CSE protein expression | 74 |
| Overweight with hypertriglyceridemia | ↓ plasma H₂S levels | 62 |

Abbreviations: CBS, cysteine β-synthase; CSE, cysteine γ-lyase; HFD, high-fat diet; MCD, methionine-choline-deficient diet; MPST, 3-mercaptopyruvate sulphurtransferase; NAFL, non-alcoholic fatty liver; NASH, non-alcoholic steatohepatitis; T2DM, type 2 diabetes mellitus.
Similarly, HFD-fed CSE KO mice exhibited reduced plasmatic thiol levels, GSH, SOD activity and increased plasma malondialdehyde (MDA) levels.  

Another study indicated that HFD-fed mice and NAFLD patients had an increased expression of hepatic MPST.  

Mitochondrial H2S oxidation as a potential player in NAFLD development

The reported effects of H2S greatly depend on its concentration, which is determined by the balance between the rates of H2S biosynthesis and oxidation. Although the majority of studies focused on the regulation of H2S levels through the modulation of its biosynthesis, mitochondrial H2S oxidation is another pathway that regulates the levels of this gasotransmitter. Given that SQR is the key regulatory enzyme in the mitochondrial H2S oxidation pathway, changes in SQR expression or activity may impact H2S signalling properties. In HFD-fed rats, Baiges et al. reported that mRNA levels of SQR and ETHE1 were decreased by more than 50% compared with rats fed chow diet. Recently, it has been reported that SQR inhibited butyrate oxidation in colonocytes. 

With this ability, SQR can exert a direct impact on IR, given that butyrate and butyrate-based compounds are known to improve liver mitochondrial respiration, mitochondrial FA β-oxidation and activate the AMP-activated protein kinase/acytety-CoA carboxylase pathway. Interestingly, a link has also been established between TST and NAFL animal models. Mice injected with an adipocyte-specific TST adenovirus resisted to HFD-induced obesity and presented smaller fat cell size despite similar food intake as the controls. This TST overexpression in adipose tissue was associated with elevated hepatic CPT1A mRNA levels and increased mitochondrial FA β-oxidation. However, whether or not TST could play a role in liver homeostasis still remains to be addressed. Regarding ETHEI mutant patients and ETHEI KO mice, abnormally high concentrations of H2S were observed in the liver, which led to Complex IV inhibition. 

Aside H2S donors, other strategies may be applied to modulate endogenous H2S production. Wang et al. have shown that HFD-fed mice subjected to moderate-intensity exercise for 24 weeks presented enhanced plasma and hepatic H2S levels as well as increased expression of CBS, CSE and MPST. These changes were accompanied by attenuated systemic IR and glucose intolerance, as well as mitigated hepatic steatosis and fibrosis. Administration of diallyl disulphides (DADs) (garlic-derived organic polysulphide compounds acting as H2S donors) to mice fed MCD diet or HFD for 4 or 20 weeks, respectively, ameliorated hepatic steatosis by downregulating mRNA levels of both SREBP-1c and apolipoprotein A1 and increasing mRNA levels of fibroblast growth factor 21. In HFD-fed mice, DADs also prevented lipotoxicity by increasing PPARα expression and inhibiting stearoyl-CoA desaturase-1 expression. As to the MCD-fed group, DADs markedly inhibited lipid peroxidation by decreasing MDA, tumour necrosis factor-alpha, interleukin-6 levels, suppressing nuclear factor kappa B activation and increasing SOD expression. 

5.2 H2S supplementation as a course of treatment for NAFLD

Recently, a growing number of evidence has shown that H2S could be used as a drug for the treatment of NAFL/ NASH (Table 2). Rats fed a methionine and choline-deficient (MCD) diet for 8 weeks had liver steatosis, inflammation and fibrosis as well as impaired hepatic H2S production. However, daily supplementation with NaHS prevented this MCD diet-induced NASH phenotype by reducing the cytochrome P450 family 2 subfamily E member 1 (Cyp2E1) expression, enhancing haeme oxygenase-1 (HO-1) expression and suppressing mitochondrial ROS production. Similarly, treatment of MCD mice with S-propargyl-cysteine (SPRC), an H2S donor, for 4 weeks significantly reduced hepatic ROS and MDA levels and increased SOD activity. In HepG2 cells, the CSE inhibitor DL-propargylglycine completely abolished the antioxidant effects of SPRC through the downregulation of Akt phosphorylation, HO-1 and CSE expression, and by inhibiting the translocation of nuclear factor erythroid 2-related factor 2 (Nrf2) to the nucleus. HFD-fed mice daily injected with NaHS for 4 weeks displayed a decrease in hepatic lipid content, lower fatty acid syntheses expression, increased carnitine palmitoyltransferase 1A (CPT1A) expression, reduced MDA levels and increased activity of both SOD and glutathione peroxidase. Liver proteomics showed that 58 proteins whose expression had changed upon HFD-feeding were normalized after NaHS treatment. The biological processes in which these proteins appear to be involved are fat digestion and absorption, FA metabolism, glutathione metabolism, drug metabolism, cytochrome P450 and steroid hormone biosynthesis. 

Aside H2S donors, other strategies may be applied to modulate endogenous H2S production. Wang et al. have highlighted the complexity of liver H2S metabolism and the elaborate regulation to which the enzymes of the transsulphuration pathway are subjected.
TABLE 2  Studies reporting the protective effects of H2S in non-alcoholic fatty liver disease (NAFLD)

| Species | Diet   | Model   | Treatment              | Effect                                           | Mechanisms                                                                 | References |
|---------|--------|---------|------------------------|-------------------------------------------------|----------------------------------------------------------------------------|------------|
| Mouse   | HFD    | NAFL    | NaHS (56 µmol/kg/day)  | Amelioration of HFD-induced NAFL                | Activation of liver autophagy via the AMPK-mTOR pathway                     | 92         |
| Mouse   | HFD    | NAFL    | NaHS (50 µmol/kg/day)  | Amelioration of HFD-induced NAFL                | Improvement of lipid metabolism and antioxidant potential                   | 91         |
| Mouse   | HFD    | NAFL    | DADs (20, 50 and 100 mg/kg) | Amelioration of HFD-induced NAFL | Increased PPARα, inhibition of SCD1, SREBP−1c and ApoA−1 | 94         |
| Mouse   | HFD    | NAFL    | Physical exercise for 24 days | Amelioration of HFD-induced NAFL | Physical exercise upregulated CBS, CSE and MPST expression, which decreased MDA levels as well as TNF-α and IL−6 expression | 93         |
| Mouse   | MCD    | NASH    | DADs (20, 50 and 100 mg/kg) | Amelioration of MCD-induced NASH | Inhibition of lipid peroxidation through the downregulation of MDA, TNF-α, IL−6 and NF-κB | 94         |
| Rat     | MCD    | NASH    | NaHS (28 µmol/kg/day)  | Amelioration of MCD-induced NASH                | Possibly through abating oxidative stress and suppressing inflammation    | 84         |
| Mouse   | MCD    | NASH    | SPRC (40 mg/kg/day)    | Amelioration of MCD-induced NASH                | Antioxidative effect through the PI3K/Akt/Nrf2/HO−1 signalling pathway     | 45         |

Abbreviations: Akt, protein kinase B; AMPK, 5′ AMP-activated protein kinase; ApoA-1, apolipoprotein A1; CBS, cysteine β-synthase; CSE, cysteine γ-lyase; DADs, diallyl disulphides; HFD, high-fat diet; HO-1, haeme oxygenase-1; IL-6, interleukin-6; MCD, methionine-choline-deficient diet; MDA, malonaldehyde; MPST, 3-mercaptopyruvate sulphurtransferase; mTOR, mechanistic target of rapamycin; NAFL, non-alcoholic fatty liver; NaHS, sodium hydrosulphide; NASH, non-alcoholic steatohepatitis; NF-κB, nuclear factor kappa B; Nrf2, nuclear factor erythroid-derived 2-like 2; PI3K, phosphoinositide 3-kinase; PPARα, peroxisome proliferator-activated receptor alpha; SCD1, stearoyl-CoA desaturase-1; SPRC, s-propargyl-cysteine; SREBP-1c, sterol regulatory element-binding protein-1c; TNFα, tumour necrosis factor-alpha.
and disruption of mitochondrial respiration. Additional studies have demonstrated that some of the metabolic inhibitory effects observed in ETHE1 KO mice could be linked to decreased mRNA levels of the E2 and E3 subunits of the branched-chain α-keto acid dehydrogenase complex (BCKDH). BCKDH is the flux-generating step in the oxidation of branched-chain amino acids (valine, leucine and isoleucine), which occurs in the mitochondria, and has some steps overlapping with mitochondrial FA β-oxidation.

Although H$_2$S production and oxidation are both important to maintain steady-state levels of H$_2$S, the way by which these pathways control H$_2$S actions in a cell may vary. H$_2$S production impacts on H$_2$S ability to modify cysteine residues and regulate protein expression/activity, whereas H$_2$S oxidation participates in mitochondrial respiration, controlling oxygen levels as well as the production of reactive sulphur species, which have lately gained importance.

Furthermore, H$_2$S biosynthesis have been associated with the development of liver steatosis, fibrosis, cirrhosis, IR and diabetes. However, the discover that H$_2$S can also be used, especially in human liver mitochondria, as an inorganic energetic substrate through its oxidation by the mitochondrial SOU, unveils a specific and previously ignored bioenergetic mechanism with promising consequences on the signaling properties of this new gasotransmitter. Given that previous studies linking cell perturbations to dysregulations in H$_2$S metabolism were mainly focused on H$_2$S biosynthesis, it becomes now imperative to explore the physiological relevance of mitochondrial H$_2$S oxidation, especially in liver pathophysiology and metabolic diseases.

6 | CONCLUDING REMARKS

In the literature, the evidence linking H$_2$S to the development of NAFLD has been piling up. Alterations in H$_2$S biosynthesis have been associated with the development of liver steatosis, fibrosis, cirrhosis, IR and diabetes. However, the discovery that H$_2$S can also be used, especially in human liver mitochondria, as an inorganic energetic substrate through its oxidation by the mitochondrial SOU, unveils a specific and previously ignored bioenergetic mechanism with promising consequences on the signaling properties of this new gasotransmitter. Given that previous studies linking cell perturbations to dysregulations in H$_2$S metabolism were mainly focused on H$_2$S biosynthesis, it becomes now imperative to explore the physiological relevance of mitochondrial H$_2$S oxidation, especially in liver pathophysiology and metabolic diseases.

CONFLICT OF INTEREST

The authors have no conflict of interest to declare.

ORCID

Carina Prip-Buus @ https://orcid.org/0000-0002-2153-7857

REFERENCES

1. Wang R. Two’s company, three’s a crowd: can H 2 S be the third endogenous gaseous transmitter? FASEB J. 2002;16(13):1792-1798. https://doi.org/10.1096/fj.02-0211hyp

2. Rubright SLM, Pearce LL, Peterson J. Environmental toxicology of hydrogen sulfide. Nitric Oxide Biol Chem. 2017;71:1-13. https://doi.org/10.1016/j.niox.2017.09.011

3. Szabo C. A timeline of hydrogen sulfide (H2S) research: from environmental toxin to biological mediator. Biochem Pharmacol. 2018;149:5-19. https://doi.org/10.1016/j.bcp.2017.09.010

4. Cooper CE, Brown GC. The inhibition of mitochondrial cytochrome oxidase by the gases carbon monoxide, nitric oxide, hydrogen cyanide and hydrogen sulfide: chemical mechanism and physiological significance. J Bioenerg Biomembr. 2008;40(5):533-539. https://doi.org/10.1007/s10863-008-9166-6

5. Abe K, Kimura H. The possible role of hydrogen sulfide as an endogenous neuromodulator. J Neurosci. 1996;16(3):1066-1071. https://doi.org/10.1523/jneurosci.16-03-01066.1996

6. Weimin Z, Jing Z, Yanjie L, Wang R. The vasorelaxant effect of H2S as a novel endogenous gaseous KATP channel opener. EMBO J. 2001;20(1):6008-6016. https://doi.org/10.1093/emboj/20.21.6008

7. Tomasova L, Dobrowolski L, Jurkowska H, et al. Intracolonic hydrogen sulfide lowers blood pressure in rats. Nitric Oxide Biol Chem. 2016;60:50-58. https://doi.org/10.1016/j.niox.2016.09.007

8. Szijártó IA, Markó L, Filipovic MR, et al. Cystathionine γ-lyase-produced hydrogen sulfide controls endothelial NO bioavailability and blood pressure. Hypertension. 2018;71(6):1210-1217. https://doi.org/10.1161/HYPERTENSIONAHA.117.10562

9. Zhen Y, Pan W, Hu F, et al. Exogenous hydrogen sulfide exerts proliferation/anti-apoptosis/angiogenesis/migration effects via amplifying the activation of NF-κB pathway in PLC/PRF/5 hepatoma cells. Int J Oncol. 2015;46(5):2194-2204. https://doi.org/10.3892/ijo.2015.2914

10. Huang S, Li H, Ge J. A cardioprotective insight of the cystathionine γ-lyase/hydrogen sulfide pathway. JIC Heart Vasc. 2015;7:51-57. https://doi.org/10.1016/j.jichj.2015.01.010

11. Hellmich MR, Coletta C, Chao C, Szabo C. The therapeutic potential of cystathionine β-Synthetase/Hydrogen sulfide inhibition in cancer. Antioxid Redox Signal. 2015;22(5):424-448. https://doi.org/10.1089/ars.2014.5933

12. Perridon BW, Leuvenink HGD, Hillebrands JL, Van Goor H, Bos EM. The role of hydrogen sulfide in aging and age-related pathologies. Aging. 2016;8(10):2264-2289. https://doi.org/10.18632/aging.101026

13. Zhang L, Yang G, Untereiner A, Ju Y, Wu L, Wang R. Hydrogen sulfide impairs glucose utilization and increases gluconeogenesis in hepatocytes. Endocrinology. 2013;154(1):114-126. https://doi.org/10.1210/en.2012-1658

14. Ju Y, Untereiner A, Wu L, Yang G. H2S-induced S-sulfhydration of pyruvate carboxylase contributes to gluconeogenesis in liver cells. Biochim Biophys Acta Gen Subj. 2015;1850(11):2293-2303. https://doi.org/10.1016/j.bbagen.2015.08.003

15. Gouben M, Andriamihaja M, Nübel T, Blachier F, Bouillaud F. Sulfide, the first inorganic substrate for human cells. FASEB J. 2007;21(8):1699-1706. https://doi.org/10.1096/fj.06-7407com

16. Wu D-D, Wang D-Y, Li H-M, Guo J-C, Duan S-F, Ji X-Y. Hydrogen sulfide as a novel regulatory factor in liver health and disease. Oxid Med Cell Longev. 2019;2019:1-16. https://doi.org/10.1155/2019/3831713

17. Szabo C, Ransy C, Módis K, et al. Regulation of mitochondrial bioenergetic function by hydrogen sulfide. Part I. Biochemical and physiological mechanisms. Br J Pharmacol. 2014;171(8):2099-2122. https://doi.org/10.1111/bph.12369
18. Mitchell TW, Savage JC, Gould DH. High-performance liquid chromatography detection of sulfide in tissues from sulfide-treated mice. *J Appl Toxicol*. 1993;13(6):389-394. https://doi.org/10.1002/jat.2550130605

19. Feng X, Zhang H, Shi M, Chen Y, Yang T, Fan H. Toxic effects of hydrogen sulfide donor NaHS induced liver apoptosis is regulated by complex IV subunits and reactive oxygen species generation in rats. *Environ Toxicol*. 2020;35(3):322-332. https://doi.org/10.1002/tox.22868

20. Tan B, Jin S, Sun J, et al. New method for quantification of gasotransmitter hydrogen sulfide in biological matrices by LC-MS/MS. *Sci Rep*. 2017;7:46278. https://doi.org/10.1038/srep46278

21. Kolluru GK, Shen X, Bir SC, Kevil CG. Hydrogen sulfide: pathophysiological roles and detection. *Nitric Oxide Biol Chem*. 2013;35:5-20. https://doi.org/10.1016/j.niox.2013.07.002

22. Tocmoto R, Wu Y, Liang D, Fogliano V, Huang D. Boiling enriches the linear polysulfides and the hydrogen sulfide-releasing activity of garlic. *Food Chem*. 2017;221:1867-1873. https://doi.org/10.1016/j.foodchem.2016.10.076

23. Koj A, Fredon J, Janik Z. [35S]thiosulphate oxidation by rat liver mitochondria in the presence of glutathione. *Biochem J*. 1967;103(3):791-795. https://doi.org/10.1042/bj1030791

24. Yang J, Minkler P, Grove D, et al. Non-enzymatic hydrogen sulfide production from cysteine in blood is catalyzed by iron and vitamin B6. *Commun Biol*. 2019;2(1):194. https://doi.org/10.1038/s42003-019-0431-5

25. Enokido Y, Suzuki E, Iwasawa K, Namekata S, Okazawa H, Kimura H. Cystathionine β-synthase, a key enzyme for homocysteine metabolism, is preferentially expressed in the radial glia/astrocyte lineage of developing mouse CNS. *FASEB J*. 2005;19(13):1854-1856. https://doi.org/10.1096/fj.05-3724fe

26. Yang G, Wu L, Jiang B, et al. H2S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine γ-lyase. *Science*. 2008;322(5901):587-590. https://doi.org/10.1126/science.1162667

27. Pedre B, Dick TP. 3-Mercaptopyruvate sulfurtransferase: an enzyme at the crossroads of sulfate sulfur trafficking. *Biol Chem*. 2021;402(3):223-237. https://doi.org/10.1515/bch-2020-0249

28. Kabil O, Vitvitsky V, Xie P, Banerjee R. The quantitative significance of the transsulfuration enzymes for H2S production in murine tissues. *Antioxid Redox Signal*. 2011;15(2):363-372. https://doi.org/10.1089/ars.2010.3781

29. Olson KR. H2S and polysulfide metabolism: conventional and unconventional pathways. *Biochem Pharmacol*. 2018;149:77-90. https://doi.org/10.1016/j.bcp.2017.12.010

30. Chiku T, Padovani D, Zhu W, Singh S, Vitvitsky V, Banerjee R. H2S biogenesis by human cystathionine γ-lyase leads to the novel sulfur metabolites lantithione and homolantithione and is responsive to the grade of hyperhomocysteinemia. *J Biol Chem*. 2009;284(17):11601-11612. https://doi.org/10.1074/jbc.M808026200

31. Singh S, Padovani D, Leslie RA, Chiku T, Banerjee R. Relative contributions of cystathionine β-synthase and γ-cystathionase to H2S biogenesis via alternative trans-sulfuration reactions. *J Biol Chem*. 2009;284(33):22457-22466. https://doi.org/10.1074/jbc.M109.010868

32. Norris EJ, Culberson CR, Narasimhan S, Clemens MG. The liver as a central regulator of hydrogen sulfide. *Shock*. 2011;36(3):242-250. https://doi.org/10.1097/SHK.0b013e318252e27

33. Shen X, Carlström M, Borrmuell S, Jäderl C, Kevil CG, Lundberg JO. Microbial regulation of host hydrogen sulfide bioavailability and metabolism. *Free Radic Biol Med*. 2013;60:195-200. https://doi.org/10.1016/j.freeradbmed.2013.02.024

34. Awano N, Wada M, Mori H, Nakamori S, Takagi H. Identification and functional analysis of Escherichia coli cysteine desulphhydrases. *Appl Environ Microbiol*. 2005;71(7):4149-4152. https://doi.org/10.1128/AEM.71.7.4149-4152.2005

35. Willis CL, Cummings JH, Neale G, Gibson GR. In vitro effects of mucin fermentation on the growth of human colonic sulphate-reducing bacteria. *Anaerobe*. 1996;2:117-122. https://quadram.ac.uk/publications/in-vitro-effects-of-mucin-fermentation-on-the-growth-of-human-colonic-sulphate-reducing-bacteria/

36. Roediger WEW. Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man. *Gut*. 1980;21(9):793-798. 10.1136/gut.21.9.793

37. Beaumont M, Andriamihaja M, Lan A, et al. Detrimental effects for colonicoytes of an increased exposure to luminal hydrogen sulfide: the adaptive response. *Free Radic Biol Med*. 2016;93:155-164. https://doi.org/10.1016/j.freeradbiomed.2016.01.028

38. Magee EA, Richardson CI, Hughes R, Cummings JH. Contribution of dietary protein to sulfide production in the large intestine: an in vitro and a controlled feeding study in humans. *Am J Clin Nutr*. 2000;72(6):1488-1494. https://doi.org/10.1093/ajcn/72.6.1488

39. Mu C, Yang Y, Luo Z, Guan L, Zhu W. The colonic microbiome and epithelial transcriptome are altered in rats fed a high-protein diet compared with a normal-protein diet. *J Nutr*. 2016;146(3):474-483. https://doi.org/10.3945/jn.115.223990

40. Kushkeyev I, Dordević D, Vitvězová M. Possible synergy effect of hydrogen sulfide and acetate produced by sulfate-reducing bacteria on inflammatory bowel disease development. *J Adv Res*. 2021;27:71-78. https://doi.org/10.1016/J.JARE.2020.03.007

41. Thompson RW, Valentine HL, Valentine WM. Cytotoxic mechanisms of hydroxysulfide anion and cyanide anion in primary rat hepatocyte cultures. *Toxocology*. 2003;188(2–3):149-159. https://doi.org/10.1016/S0300-483X(03)00079-9

42. Leschelle X, Goubren M, Andriamihaja M, et al. Adaptive metabolic response of human colonic epithelial cells to the adverse effects of the luminal compound sulfide. *Biochim Biophys Acta Gen Subj*. 2005;1725(2):201-212. https://doi.org/10.1016/j.bbagrm.2005.06.002

43. Truong DH, Eghbal MA, Hindmarsh W, Roth SH, O’Brien PJ. Molecular mechanisms of hydrogen sulfide toxicity. *Drug Metab Rev*. 2006;38(4):733-744. https://doi.org/10.1080/03602350600959607

44. Eghbal MA, Pennefather PS, O’Brien PJ. H2S cytotoxicity mechanism involves reactive oxygen species formation and mitochondrial depolarisation. *Toxicology*. 2004;203(1–3):69-76. https://doi.org/10.1016/j.tox.2004.05.020

45. Li W, Ma F, Zhang L, et al. S-Propargyl-cysteine exerts a novel protective effect on methionine and choline deficient diet-induced fatty liver via Akt/Nrf2/HO-1 pathway. *Oxid Med Cell Longev*. 2016;2016:1–17. https://doi.org/10.1155/2016/4690857
46. Powell MA, Somero GN. Hydrogen sulfide oxidation is coupled to oxidative phosphorylation in mitochondria of Solemya reidi. Science. 1986;233(4763):563-566. https://doi.org/10.1126/science.233.4763.563

47. Grieshaber MK, Völke S. Animal adaptations for tolerance and exploitation of poisonous sulfide. Annu Rev Physiol. 1998;60:33-53. https://doi.org/10.1146/annurev.physiol.60.1.33

48. Hildebrandt TM, Grieshaber MK. Three enzymatic activities catalyze the oxidation of sulfide to thiosulfate in mammalian and invertebrate mitochondria. FEBS J. 2008;275(13):3352-3361. https://doi.org/10.1111/j.1742-4658.2008.06482.x

49. Ackermann M, Kubitza M, Maier K, Brawanski A, Hauska G, Piña AL. The vertebrate homolog of sulfide-quinone reductase is expressed in mitochondria of neuronal tissues. Neuroscience. 2011;199:1-12. https://doi.org/10.1016/j.neuroscience.2011.10.044

50. Bartholomew TC, Powell GM, Dodson KS, Curtis CG. Oxidation of sodium sulfide by rat liver, lungs and kidney. Biochem Pharmacol. 1980;29(18):2431-2437. https://doi.org/10.1016/0006-2952(80)90346-9

51. Levitt MD, Furne J, Springfield J, Suarez F, DeMaster E. Detoxification of hydrogen sulfide and methanethiol in the cecal mucosa. J Clin Invest. 1999;104(8):1107-1114. https://doi.org/10.1172/JCI77112

52. Helmy N, Prip-Buus C, Vons C, et al. Oxidation of hydrogen sulfide by human liver mitochondria. Nitric Oxide. 2014;41:105-112. https://doi.org/10.1016/j.niox.2014.05.011

53. Abou-Hamdan A, Guedouari-Bounihi H, Lenoir V, Andriamihaja M, Blachier F, Bouillaud F. Oxidation of H2S in mammalian cells and mitochondria. Methods Enzymol. 2015;554:201-228. Academic Press Inc. https://doi.org/10.1016/bs.mie.2014.11.042

54. Módis K, Coletta C, Erdélyi K, Papapetropoulos A, Szabo C. Intramitochondrial hydrogen sulfide production by 3-mercaptopyruvate sulfurtransferase maintains mitochondrial electron flow and supports cellular bioenergetics. FASEB J. 2013;27(2):601-611. https://doi.org/10.1096/fj.12-216507

55. Tsai C-Y, Peh MT, Feng W, Dymock BW, Moore PK. Hydrogen sulfide promotes adipogenesis in 3T3L1 cells. Wallace J, ed. PLoS One. 2015;10(5):e0119511. https://doi.org/10.1371/journal.pone.0119511

56. Lagouette E, Mimoun S, Andriamihaja M, Chaumontet C, Blachier F, Bouillaud F. Oxidation of hydrogen sulfide remains a priority in mammalian cells and causes reverse electron transfer in colonocytes. Biochim Biophys Acta Bioenerg. 2010;1797(8):1500-1511. https://doi.org/10.1016/j.bbabio.2010.04.004

57. Módis K, Ju Y, Ahmad A, et al. Sulfhydration of ATP synthase by hydrogen sulfide stimulates mitochondrial bioenergetics. Pharmacol Res. 2016;113(Pt A):116-124. https://doi.org/10.1016/j.phrs.2016.08.023

58. Rui L. Energy metabolism in the liver. Compr Physiol. 2014;4(1):177-197. https://doi.org/10.1002/cphy.c130024

59. Gao B, Il JW, Tian Z. Liver: an organ with predominant innate immunity. Hepatology. 2008;47(2):729-736. https://doi.org/10.1002/hep.22034

60. Chen K, Zhong J, Hu L, et al. The role of xenobiotic receptors on hepatic glycolipid metabolism. Curr Drug Metab. 2018;20(1):29-35. https://doi.org/10.2174/138920201966180918152241

61. Untereiner AA, Wang R, Ju Y, Wu L. Decreased gluconeogenesis in the absence of cystathionine gamma-lyase and the underlying mechanisms. Antioxid Redox Signal. 2016;24(3):129-140. https://doi.org/10.1089/ars.2015.6369

62. Sun L, Zhang S, Yu C, et al. Hydrogen sulfide reduces serum triglyceride by activating liver autophagy via the AMPK-mTOR pathway. Am J Physiol Endocrinol Metab. 2015;309(11):E925-E935. https://doi.org/10.1152/ajpendo.00294.2015

63. Kim D, Chang GE, Kwak MS, et al. Body fat distribution and risk of incident and regressed nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2016;14(1):132-138.e4. https://doi.org/10.1016/j.cgh.2015.07.024

64. Yin P, Zhao C, Li Z, et al. Sp1 is involved in regulation of cystathionine γ-lyase gene expression and biological function by PI3K/Akt pathway in human hepatocellular carcinoma cell lines. Cell Signal. 2012;24(6):1229-1240. https://doi.org/10.1016/j.cellsig.2012.02.003

65. Geng B, Cai B, Liao F, et al. Increase or decrease hydrogen sulfide exert opposite lipolysis, but reduce global insulin resistance in high fatty diet induced obese mice. PLoS One. 2013;8(9):e73892. https://doi.org/10.1371/journal.pone.0073892

66. Feng X, Chen Y, Zhao J, Tang C, Jiang Z, Geng B. Hydrogen sulfide from adipose tissue is a novel insulin resistance regulator. Biochem Biophys Res Comm. 2009;380(1):153-159. https://doi.org/10.1016/j.bbrc.2009.01.059

67. Yusuf M, Huat BTK, Hsu A, Whiteman M, Bhatia M, Moore PK. Streptozotocin-induced diabetes in the rat is associated with enhanced tissue hydrogen sulfide biosynthesis. Biochem Biophys Res Comm. 2005;333(4):1146-1152. https://doi.org/10.1016/j.bbrc.2005.06.021

68. Watanabe M, Osada J, Aratani Y, et al. Mice deficient in cystathionine β-synthase: animal models for mild and severe homocyst(e)inemia. Proc Natl Acad Sci USA. 1995;92(5):1585-1589. https://doi.org/10.1073/pnas.92.5.1585

69. Robert K, Nehmé J, Bourdon E, et al. Cystathionine β synthase deficiency promotes oxidative stress, fibrosis, and steatosis in mice liver. Gastroenterology. 2005;128(5):1405-1415. https://doi.org/10.1053/j.gastro.2005.02.034

70. Namekata K, Enokido Y, Ishii I, Nagai Y, Harada T, Kimura H. Abnormal lipid metabolism in cystathionine β-synthase-deficient mice, an animal model for hyperhomocysteinemia. J Biol Chem. 2004;279(51):52961-52969. https://doi.org/10.1074/jbc.M406820200

71. Hamelet J, Demuth K, Paul JL, Delabar JM, Janel N. Hyperhomocysteinemia due to cystathionine beta synthase deficiency induces dysregulation of genes involved in hepatic lipid homeostasis in mice. J Hepatol. 2007;46(1):151-159. https://doi.org/10.1016/j.jhep.2006.07.028

72. Zhang T, Lu R, Chen Y, et al. Hyperhomocysteinemia and dyslipidemia in point mutation G307S of cystathionine β-synthase-deficient rabbit generated using CRISPR/Cas9. Lipids Health Dis. 2020;19(1):224. https://doi.org/10.1186/s12944-020-01394-5

73. Jacobs RL, Jiang H, Kennelly JP, et al. Cystathionine beta-synthase deficiency alters hepatic phospholipid and choline metabolism: post-translational repression of phosphatidylethanolamine N-methyltransferase is a consequence rather than a cause of liver injury in homocystinuria. Mol Genet Metab. 2017;120(4):325-336. https://doi.org/10.1016/j.ymgme.2017.02.010

74. Li M, Xu C, Shi J, et al. Fatty acids promote fatty liver disease via the dysregulation of 3-mercaptopuruvate sulfurtransferase/
hydrogen sulfide pathway. Gut. 2018;67(12):2169-2180. https://doi.org/10.1136/gutjnl-2017-313778

75. Horsman JW, Miller DL. Mitochondrial sulfide quinine oxidoreductase prevents activation of the unfolded protein response in hydrogen sulfide. J Biol Chem. 2016;291(10):5320-5325. https://doi.org/10.1074/jbc.M115.697102

76. Friederich MW, Elias AF, Kuster A, et al. Pathogenic variants in SQOR encoding sulfidequinone oxidoreductase are a potentially treatable cause of Leigh disease. J Inherit Metab Dis. 2020;43(5):1024-1036. https://doi.org/10.1002/jimd.12232

77. Hine C, Harputlugil E, Zhang Y, et al. Endogenous hydrogen sulfide production is essential for dietary restriction benefits. Cell. 2015;160(1-2):132-144. https://doi.org/10.1016/j.cell.2014.11.048

78. Shirouzu K, Tokuda K, Marutani E, Lefer D, Wang R, Ichinose F. Cystathionine γ-Lyase deficiency protects mice from Galactosamine/lipopolysaccharide-induced acute liver failure. Antioxid Redox Signal. 2014;20(2):204-216. https://doi.org/10.1089/ars.2013.3534

79. Paschos P, Paletas K. Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia. 2009;13(1):9-19.

80. Petta S, Gastaldelli A, Rebelos E, et al. Pathophysiology of non alcoholic fatty liver disease. Int J Mol Sci. 2016;17(12):2082. https://doi.org/10.3390/ijms17122082

81. Peh MT, Anwar AB, Ng DSW, Atan MSBM, Kumar SD, Moore PK. Effect of feeding a high fat diet on hydrogen sulfide (H2S) metabolism in the mouse. Nitric Oxide. 2014;41:138-145. https://doi.org/10.1016/j.niox.2014.03.002

82. Bravo E, Palleschi S, Aspichueta P, et al. High fat diet-induced non alcoholic fatty liver disease in rats is associated with hyperhomocysteinemia caused by down regulation of the trans-sulphuration pathway. Lipids Health Dis. 2011;10:60. https://doi.org/10.1186/1476-511X-10-60

83. Whiteman M, Gooding KM, Whatmore JL, et al. Adiposity is a major determinant of plasma levels of the novel vasodilator hydrogen sulphide. Diabetologia. 2010;53(8):1722-1726. https://doi.org/10.1007/s00125-010-1761-5

84. Luo Z-L, Tang L-J, Wang T, et al. Effects of treatment with hydrogen sulfide on methionine-choline deficient diet-induced non-alcoholic steatohepatitis in rats. J Gastroenterol Hepatol. 2014;29(1):215-222. https://doi.org/10.1111/jgh.12389

85. Hwang S-Y, Sarna LK, Siow YL, Karmin O. High-fat diet stimulates hepatic cystathionine β-synthase and cystathionine γ-lyase expression. Can J Physiol Pharmacol. 2013;91(11):913-919. https://doi.org/10.1139/cjpp-2013-0106

86. Wijekoon EP, Hall B, Ratnam S, Brosnan ME, Zeisel SH, Brosnan JT. Homocysteine metabolism in ZDF (Type 2) diabetic rats. Diabetes. 2005;54(11):3245-3251. https://doi.org/10.2337/diabetes.54.11.3245

87. Guo W, Li D, You V, et al. Cystathionine γ-lyase deficiency aggravates obesity-related insulin resistance via FoxO1-dependent hepatic gluconeogenesis. FASEB J. 2019;33(3):4212-4224. https://doi.org/10.1096/fj.201801894R

88. Mani S, Li H, Yang G, Wu L, Wang R. Deficiency of cystathionine gamma-lyase and hepatic cholesterol accumulation during mouse fatty liver development. Sci Bull. 2015;60(3):336-347. https://doi.org/10.1007/s11434-014-0722-7

89. Ali A, Zhang Y, Fu M, et al. Cystathionine gamma-lyase/ H2S system suppresses hepatic acetyl-CoA accumulation and nonalcoholic fatty liver disease in mice. LifeSci. 2020;252:117661. https://doi.org/10.1016/j.lfs.2020.117661

90. Mani S, Li H, Untereiner A, et al. Decreased endogenous production of hydrogen sulfide accelerates atherosclerosis. Circulation. 2013;127(25):2532-2534. https://doi.org/10.1161/CIRCULATIONAHA.113.002208

91. Wijekoon EP, Hall B, Ratnam S, Brosnan ME, Zeisel SH, Brosnan JT. Homocysteine metabolism in ZDF (Type 2) diabetic rats. Diabetes. 2005;54(11):3245-3251. https://doi.org/10.1007/s11434-014-0722-7

92. Liu Z, Liu M, Fan M, et al. Metabolomic-proteomic combination analysis reveals the targets and molecular pathways associated with hydrogen sulfide alleviating NAFLD. Life Sci. 2021;264:118629. https://doi.org/10.1016/j.lfs.2020.118629

93. Wang B, Zeng J, Gu Q. Exercise restores bioavailability of hydrogen sulfide and promotes autophagy influx in livers of mice fed with high-fat diet. Can J Physiol Pharmacol. 2017;95(6):667-674. https://doi.org/10.1139/cjpp-2016-0611

94. Zhang N, Wang Y, Zhang J, et al. Diallyl disulfide attenuates non-alcoholic steatohepatitis by suppressing key regulators of lipid metabolism, lipid peroxidation and inflammation in mice. Mol Med Rep. 2019;20(2):1363-1372. https://doi.org/10.3892/mmr.2019.10316

95. Baiges I, Palmfeldt J, Bladé C, Gregersen N, Arola L. Lipogenesis is decreased by grape seed proanthocyanidins according to liver proteomics of rats fed a high fat diet. Mol Cell Proteomics. 2010;9(7):1499-1513. https://doi.org/10.1074/mcp.M000555-MCP201

96. Mollica MP, Raso GM, Cavaliere G, et al. Butyrate regulates liver mitochondrial function, efficiency, and dynamics in insulin-resistant obese mice. Diabetes. 2017;66(5):1405-1418. https://doi.org/10.2337/db16-0924

97. Morton NM, Beltram J, Carter RN, et al. Genetic identification of thiosulfate sulfurtransferase as an adipocyte-expressed antidiabetic target in mice selected for leanness. Nat Med. 2016;22(7):771-779. https://doi.org/10.1038/nm.4115

98. Tam A, AlDahheri NS, Mysore K, et al. Improved clinical outcome following liver transplant in patients with ethylmalonic encephalopathy. Am J Med Genet A. 2019;179(6):1015-1019. https://doi.org/10.1002/ajmg.a.61104

99. Hildebrandt TM, Di Meo I, Zeviani M, Visconi C, Braun HP. Proteome adaptations in Ethel-deficient mice indicate a role in lipid catabolism and cytoskeleton organization via post-translational protein modifications. Biosci Rep. 2013;33(4):575-584. https://doi.org/10.1042/BRS20130051

100. Filipovic MR, Zivanovic J, Alvarez B, Banerjee R. Chemical biology of H2S signaling through persulfidation. Chem Rev. 2018;118(3):1253-1337. https://doi.org/10.1021/acs.chemrev.7b00205

How to cite this article: Mateus I, Prip-Buus C. Hydrogen sulphide in liver glucose/lipid metabolism and non-alcoholic fatty liver disease. Eur J Clin Invest. 2022;52:e13680. https://doi.org/10.1111/eji.13680